Although automobile manufactures are always coming out with new and improved safety features, car accidents remain a leading cause of death and injury in the United States.
According to the NHTSA (National Highway Traffic-Safety Administration), the amount of traffic accidents has slowly decreased in Texas, but on average there are about still about 3,300 fatalities a year in the Lone Star State alone. Surprisingly, at least 10% of those accidents involve drivers who are 16-20 years of age.
The main causes of most automobile accidents are drunk or distracted drivers. Despite all the public service announcements and growing awareness of the dangers of using cellular phones while driving, recent surveys show that most drivers are willing to risk others’ lives and their own to answer a call or text while behind the wheel. Texting increases the risk of having a car crash by a whopping 23%! For more information about distracted driving visit www.Distraction.gov.
The highest price we pay for these car crashes is the loss of human lives, but there are many non-fatal accidents that also incur huge costs. The CDC (Center for Disease Control) statistics for 2010 show that the cost of medical and productivity losses associated with car crashes was over $99 billion, or $500 per licensed driver in the US.
Our law firm has helped thousands of people recover millions of dollars they were owed for their injuries from car crashes. If you or someone you care about has been injured in a car crash, call Dallas’s premier auto wreck attorneys today at 1.877.308.7900 or email me: email@example.com.
Chronic kidney failure may be due to diabetes or low blood sugar, and affects approximately 2 million people. In the US, kidney disease affects over 2 out of every 1,000 people. In kidney dialysis, a machine called a dialyzer uses a solution to clean the blood. Products used in this process were GranuFlo and NaturaLyte, which may produce an excess of bicarbonate leading to a condition known as metabolic alkalosis in which pH levels in the body are elevated. This condition can cause low blood pressure, heart attacks, serious heart injuries and sudden cardiac-related deaths.
GranuFlo and NaturaLyte are manufactured and marketed by Fresenius Medical Care (FMC). IN 2011, Fresenius had a whopping net revenue of $12.8 billion and is the US leader in the dialysis market. FMC also owns over 1,800 U.S. Dialysis clinics that perform these treatments with GranuFlo. Additionally, approximately 125,000 patients are treated with GranuFlo at other clinics.
At the present time, Fresenius Medical Care has numerous suits against it since 941 patients suffered from cardiac arrest in 2010 after being treated with GranuFlo products. In March of 2012, the FDA recalled both GranuFlo and NaturaLyte. Unfortunately, this recall came far too late to save countless patients who experienced severe symptoms or died from these products. Worst of all, patients or survivors of loved ones who died say they were not informed of the dangers of using GranuFlo or NaturaLyte.
A federal jury in Dallas on Thursday ordered Johnson & Johnson and its DePuy Orthopedics unit to pay $247 million to six patients who said they were injured by defective Pinnacle hip implants.
Delivering a third straight win to patients, the jury found that the metal-on-metal hip implants were defectively designed and that the companies failed to warn consumers about the risks.
Six New York residents implanted with the devices said they experienced tissue death, bone erosion and other injuries they blamed on design flaws.
J&J, which faces more than 9,700 Pinnacle lawsuits in state and federal courts across the United States, said in a statement it would immediately begin the appeal process.
A DePuy spokeswoman said the company was still “committed to the long-term defense of the allegations in these lawsuits,” adding that the metal-on-metal hip implants were backed by a strong record of clinical data showing they were effective.
Plaintiffs claimed the companies falsely promoted the device, most commonly used to treat joint failure caused by osteoarthritis, by saying it lasted longer than similar implants that include ceramic or plastic materials.
“We thank this jury for sending a very strong message about the responsibility the defendants have to take care of their consumers,” Mark Lanier, who represented the New York patients, said in a statement.
Thursday’s verdict came in the fourth test trial over the devices in Dallas federal court, where some 9,000 of the cases are pending. Test cases have been selected for trial, and their outcomes will help gauge the value of the remaining claims and inform potential settlement talks.
J&J won the first Pinnacle test trial in 2014, but subsequent juries determined the companies to be liable.
A jury in March 2016 awarded five Texas plaintiffs $500 million in damages. That award was later cut to $150 million.
J&J and DePuy were also found liable at a trial in March, during which a jury awarded six California patients $1 billion – a verdict that was later reduced to $543 million.
DePuy ceased selling the metal-on-metal Pinnacle devices in 2013 after the U.S. Food and Drug Administration strengthened its artificial hip regulations.
PINNACLE HIP REPLACEMENT PROBLEMS
The Pinnacle hip replacement is a total hip replacement system manufactured by Johnson & Johnson subsidiary, DePuy Orthopaedics. Approved by the U.S. Food and Drug Administration in 2000, the DePuy Pinnacle Hip Acetabular Cup System was the predecessor to the now recalled DePuy ASR XL Acetabular System and the ASR Hip Resurfacing System. The DePuy Pinnacle hip replacement is a total hip arthroplasty intended to provide increased mobility while reducing pain in patients with damaged hip joints.
Like patients who received ASR hip replacements, it appears that those who received the DePuy Pinnacle hip replacement also face an increased risk of hip failure. This is because the two hip replacement systems had similar design defects, which can lead to severe pain, dislocation of the hip implant and hip replacement failure.
Although the DePuy Pinnacle hip replacement implants were not part of the August 2010 ASR hip recall, they are also metal-on-metal devices, and therefore carry many of the adverse side effects commonly experienced by ASR hip implant recipients. Due to the defective design associated with metal-on-metal implants, as with the ASR hip systems, many recipients of DePuy Pinnacle hip replacement implants have had to undergo painful revision surgeries.
DEPUY PINNACLE HIP REPLACEMENT COMPLICATIONS
Lawsuits involving the DePuy Pinnacle Hip Implant alleged that the all-metal version is similar in design to DePuy’s ASR hip implant, another metal-on-metal device that was recalled in August 2010. The lawsuits claimed that the all-metal version of the DePuy Pinnacle Hip Implant caused patients to suffer the same types of complications that prompted the ASR Hip Implant recall, including:
DePuy Pinnacle failure
Elevated metallic levels
Need for a second hip replacement surgery
Hip implant loosening
Difficulty walking or standing
Premature failure of the implant requiring revision surgery
Additionally, patients who received the DePuy Pinnacle hip replacement implants should be aware of symptoms associated with metal toxicity, or metallosis. The effects of metallosis can manifest outside of the hip region. Therefore, individuals who received a DePuy Pinnacle hip replacement should be mindful of any changes in their overall health and pay close attention to any symptoms related to their:
Heart (chest pain, shortness of breath)
Nerves (numbness, weakness, change in vision or hearing)